Mineralys Therapeutics, Inc.
Every calculator, already run for MLYS
Open the full toolkit →You have the numbers on MLYS. Get the argument.
A written report on which of these readings actually decide the outcome for Mineralys Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
11 analysts covering MLYSAnalyst Price Target Disagreement for Mineralys Therapeutics, Inc.
Wall Street's bull case implies +277% from the current price; the bear case implies +28%. A 249% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for MLYS
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
MLYS — frequently asked
Is MLYS a buy right now?
Wall Street's consensus rating on Mineralys Therapeutics, Inc. is Strong Buy across 11 analysts, with a mean price target of $43.56 (+193% vs. the current $14.85). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
What is the analyst price target disagreement for Mineralys Therapeutics, Inc.?
Analysts covering Mineralys Therapeutics, Inc. (MLYS) range from a bear-case target of $19.00 to a bull-case high of $56.00, with a mean consensus target of $43.56 across 9 analysts. The spread of $37.00 (249% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Mineralys Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Mineralys Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full MLYS research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Mineralys Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.